Samtidig indgivelse af tenofovirdisoproxilfumarat og didanosin resulterer i en 40- 60% stigning i systemisk eksponering over for didanosin, hvilket kan øge risikoen for didanosinrelaterede bivirkninger.
fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse events.